Pseudo-neurotic schizophrenia: P. Hoch and P. Polatin, «Pseudoneurotic forms of schizophrenia»,
US/UK diagnostic project: J. E Cooper et at., «Psychiatric diagnosis in New York and London»,
DSM-IV: American Psychiatric Association,
Present State Examination: J. K. Wing, J. E. Cooper, and N. Sartorius,
Schneider's first rank symptoms: C. S. Mellors, «First-rank symptoms of schizophrenia»,
Is there a form of schizophrenia with a good outcome?: E C. Johnstone et al., «The nature of „transient“ and „partial“ psychoses: findings from the Northwick Park „Functional“ Psychosis Study»,
The Northwick Park first episode study: J. F. MacMillan, T. J. Crow, A. L. Johnson, and E. G. Johnstone, «Northwick Park study of first episodes of schizophrenia III. Short-term outcome in trial entrants and trial eligible patients»,
The outcome of schizophrenia: World Health Organization,
Edinburgh high-risk study: E. C. Johnstone et al., «Edinburgh highrisk study — findings after four years. Demographic, attainment and psychopathological issues»,
The genetic «spectrum» of schizophrenia: K. S. Kendler et al., «The structure of schizotypy — a pilot multitrait twin study».
Глава 3
The central executive: A. Baddeley,
IQ in schizophrenia: C. D. Frith, J. Leary, C. Cahill and E. C. Johnstone, «Performance on psychological tests. Demographic and clinical correlates of the results of these tests»,
IQ. decline in schizophrenia: J. Rabinowitz et al., «Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital — cross-sectional analysis»,
IQ and institutionalization: E. C. Johnstone et al., «The dementia of dementia
IQ and community care: C. Kelly et al., «Nithsdale Schizophrenia Surveys 20 — cognitive function in a catchment-area-based population of patients with schizophrenia»,
IQ and drugs: S. Mohamed et al., «Generalized cognitive deficits in schizophrenia — a study of first-episode patients».
The core cognitive impairment in schizophrenia: B. Elvevag and T. E. Goldberg, «Cognitive impairment in schizophrenia is the core of the disorder».
Motivation in schizophrenia: S. G. Heilman et al., «Monetary reinforcement and Wisconsin Card Sorting performance in schizophrenia: why show me the money?»,
Single case approach: T. Shallice, P. W. Burgess, and C. D. Frith, «Can the neuropsychological case-study approach be applied to schizophrenia?».
Classifying symptoms: T. J. Crow, «Molecular pathology of schizophrenia: more than one disease process?»,
Intellectual functioning and symptoms: E. C. Johnstone and C. D. Frith, «Validation of three dimensions of schizophrenic symptoms in a large unselected sample of patients».
Genius and madness: N. C. Andreasen, «Creativity and mental illness: prevalence rates in writers and their first-degree relatives».
Superior abilities in the relatives of patients with schizophrenia: J. L. Karlsson, «Mental abilities of male relatives of psychotic patients»,
Глава 4
Amphetamine psychosis: P. H. Connell,
Experimental studies of amphetamine: J. D. Griffith, J. H. Cavanaugh, J. Held, et al., «Experimental psychosis induced by the administration of d-amphetamine»,
В. M. Angrist and S. Gershon, «The phenomenology of experimentally induced amphetamine psychosis: Preliminary observations».
Amphetamine and dopamine: L. Kokkinidis and H. Anisman, «Amphetamine psychosis and schizophrenia — a dual model»,
Cannabis and schizophrenia: S. Andreasson, A. Engstrom, P. Allebeck, and U. Rydberg, «Cannabis and schizophrenia — a longitudinal study of Swedish conscripts».
The cannabis receptor: M. Glass, «The role of cannabinoids in neurodegenerative diseases».
PCP and schizophrenia: D. C. Javitt and S. R. Zukin, «Recent advances in the phencyclidine model of schizophrenia»,
Discovery of antipsychotic drugs: J. Delay and P. Deniker, «Le traitement des psychoses par une methode neurolyptique derivee de l'hibernotherapie», in
Efficacy of antipsychotic drugs: J. M. Davis and D. L. Gerver, «Neuroleptics — clinical use in psychiatry», in
Dopamine and Parkinson's disease: 0. Hornykiewicz, «Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA)»,
The dopamine theory of schizophrenia: A. Carlsson and M. Lindquist, «Effect of chlorpromazine and haloperidol of formation of 3-methoxytyramine and normetanephrine in mouse brain»,
Dopamine blockade and the efficacy of antipsychotic drugs: P. Seeman et al., «Antipsychotic drug doses and neuroleptic/dopamine receptors».
Atypical antipsychotics: J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, «Clozapine for the treatment- resistant schizophrenic. A double-blind comparison with chlorpromazine».
A revised dopamine theory of schizophrenia: S. Kapur and G. Remington, «Dopamine D(2) receptors and
